LIVINGSTON, NJ / ACCESSWIRE / December 3, 2019 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced that it will be presenting at the 12th Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Bel Air Hotel in Bel Aire, California.
Len Osser, Interim Chief Executive Officer, is scheduled to present on Tuesday, December 10th at 3:40pm, Pacific Time, with one-on-one meetings to be held throughout the conference.
The LD Micro Main Event is one of the nation’s largest independent conferences for micro-cap companies, with over 250 names presenting to more than 1,400 attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest and issuers, as well as evening social events.
To schedule a one-on-one meeting with Milestone Scientific, you may submit your request online via the link provided upon registration or email your request to email@example.com. To register for the conference, contact David Scher at firstname.lastname@example.org or visit www.ldmicro.com/events.
View Milestone Scientific’s LD Micro profile here: https://www.ldmicro.com/profile/mlss
Profiles powered by LD Micro – News Compliments of Accesswire.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
SOURCE: Milestone Scientific Inc.
View source version on accesswire.com: